Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect

Project: Research project

Project Details


This phase 1b trial studies the biologic effect of 9cUAB30 on early stage breast cancer. 9cUAB30 is a retinoid X receptor (RXR)-selective retinoid that acts in a tissue selective manner with the goal of minimizing side effects, a necessary feature of agents under development for cancer prevention.
Effective start/end date5/10/212/28/22


  • University of Wisconsin-Madison (Agmt 0000001301//Task Order HHSN26100009)
  • National Cancer Institute (Agmt 0000001301//Task Order HHSN26100009)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.